EXOB 001
Alternative Names: EXOB-001Latest Information Update: 28 Aug 2023
At a glance
- Originator EXO Biologics
- Class Exosome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Bronchopulmonary dysplasia
Most Recent Events
- 17 Jul 2023 Preclinical trials in Bronchopulmonary dysplasia in Belgium(Intratracheal)
- 17 Jul 2023 EXO Biologics plans a phase I/II EVENEW trial for Bronchopulmonary Dysplasia (Neonates, Prevention)
- 11 Jul 2023 European Medicines Agency (EMA) approves IND application for EXOB 001 in (indication) Bronchopulmonary Dysplasia